notori
biotechnolog
advanc
last
decad
allow
develop
experiment
method
understand
molecular
mechan
gene
new
therapeut
approach
gene
therapi
matur
viabl
practic
method
potenti
cure
varieti
human
ill
nucleicacidbas
drug
avail
control
progress
genet
diseas
inhibit
gene
express
activ
gene
product
new
therapeut
strategi
employ
wide
rang
molecular
tool
bacteri
plasmid
contain
transgen
insert
rna
interfer
aptam
nucleicacid
base
constitut
confer
lower
immunogen
potenti
result
high
stringenc
select
larg
molecular
varieti
drug
high
affi
niti
select
target
howev
nucleic
acid
poor
biostabl
thu
requir
chemic
modifi
cation
deliveri
system
maintain
activ
eas
cellular
intern
review
discuss
mechan
action
applic
therapi
base
nucleic
acid
aptam
rna
interfer
well
platform
cellular
uptak
intracellular
deliveri
therapeut
oligonucleotid
tradeoff
discoveri
dna
molecul
one
import
achiev
understand
fundament
basi
life
untap
therapeut
potenti
reveal
therapi
base
nucleic
acid
na
includ
plasmid
contain
transgen
use
gene
therapi
antisens
antigen
oligonucleotid
ribozym
dnazym
dna
rna
aptam
small
interf
rna
develop
past
coupl
decad
crook
stull
szoka
patil
et
al
ulrich
et
al
although
nabas
drug
earli
stage
clinic
trial
molecul
class
emerg
recent
year
promis
drug
candid
abl
act
larg
rang
diseas
includ
aid
cancer
neurolog
cardiovascular
disord
stull
szoka
patil
et
al
ulrich
et
al
sequenc
human
genom
transcriptom
proteom
project
provid
addit
platform
advanc
nabas
therapi
suppli
new
target
design
screen
select
drug
one
signifi
cant
advantag
nabas
drug
convent
pharmaceut
drug
high
select
toward
molecular
target
result
specifi
c
physiolog
action
drug
use
investig
genet
diseas
condit
use
prophylact
measur
therebi
prevent
diseas
progress
andor
complic
earli
stage
instanc
gene
therapi
usual
involv
correct
malfunct
gene
introduct
express
correct
copi
thu
result
correct
protein
product
similarli
nabas
drug
involv
gene
ablat
turn
select
gene
guarante
specifi
c
control
diseas
state
thu
least
theoret
use
nabas
therapi
result
null
minim
collater
effect
compar
convent
often
less
specifi
c
pharmaceut
drug
howev
effect
na
drug
human
exposit
must
complet
understood
emphasi
unforeseen
longterm
effect
yet
littl
knowledg
pharmacokinet
nabas
drug
greatest
challeng
face
therapeut
util
na
overcom
low
cellular
absorpt
inher
highli
polar
molecular
structur
innat
abil
drug
cross
membran
minim
normal
circumst
addit
low
biostabl
result
unpredict
pharmacokinet
na
molecul
happen
enter
cell
subsequ
subject
intracellular
degrad
nucleas
effect
narrow
drug
activ
timespan
fi
rst
nadrug
approv
novemb
fda
denomin
vitraven
oligonucleotid
discov
isi
antisens
drug
treatment
cytomegaloviru
retin
aid
patient
perri
balfour
vitraven
market
novarti
ophthalm
reveal
power
aid
medic
preclin
studi
antisens
inhibit
craf
kinas
associ
reduct
format
new
blood
vessel
eye
involv
agerel
macular
degener
amd
diabet
retinopathi
dani
et
al
approv
fi
rst
nucleicacid
base
drug
serv
encourag
scientist
use
selex
systemat
evolut
ligand
exponenti
enrich
rna
interfer
rnai
approach
drug
develop
see
scheme
oligonucleotid
action
gene
express
protein
aciv
artifi
cial
modul
gene
express
mainli
base
inhibit
gene
transcript
mrna
degrad
phenomenon
rnai
first
observ
nematod
worm
caenorhabd
elegan
respons
doublestrand
rna
dsrna
treatment
result
sequencespecifi
c
gene
silenc
fire
et
al
later
phenomenon
observ
larg
varieti
biolog
system
includ
sever
invertebr
recent
also
vertebr
xenopu
mice
nakano
et
al
wianni
zernickagoetz
induct
rnai
small
doubl
strand
rna
term
small
interf
rna
sirna
produc
cleavag
long
dsrna
tuschl
et
al
zamor
et
al
hamilton
baulcomb
hammond
et
al
cytoplasm
highli
conserv
dicer
protein
member
famili
rnase
iiilik
enzym
form
characterist
long
dsrna
duplex
symmetr
twoto
threenucleotid
overhang
bernstein
et
al
elbashir
et
al
duplex
smallinterf
si
rna
product
long
dsrna
cleavag
integr
risc
complex
rnainduc
silenc
complex
complex
becom
activ
unwind
duplex
upon
loss
one
strand
sirna
duplex
rna
helicas
activ
depend
sever
target
sirna
properti
entir
understood
risc
either
specif
cleav
degrad
target
mrna
yekta
et
al
meister
et
al
zamor
et
al
bagga
et
al
giraldez
et
al
wu
et
al
inhibit
translat
without
initi
sequencespecifi
c
mrna
degrad
process
olsen
ambro
reinhart
et
al
wightman
et
al
target
mrna
cleav
risc
complex
middl
complementari
region
ten
nucleotid
upstream
nucleotid
pair
end
guid
sirna
elbashir
et
al
cleavag
reaction
guid
risc
requir
atp
et
al
zamor
howev
multipl
round
mrna
cleavag
requir
releas
cleav
mrna
product
effi
cient
presenc
atp
zamor
dsrna
endogen
origin
dicer
cleavag
product
name
micro
rna
mirna
mirnaguid
mechan
translat
regul
well
understood
studi
mutant
transgen
c
elegan
show
mirna
inhibit
targetprotein
synthesi
without
affect
mrna
level
bartel
target
mrna
contain
threeprim
untransl
region
sever
bind
site
mirna
target
mirna
found
associ
polyribosom
suggest
mirna
block
translat
elong
termin
rather
translat
initi
olsen
ambro
seggerson
et
al
use
protein
mutant
variou
gene
involv
rnai
process
identifi
ed
includ
highli
homolog
helicas
enzym
involv
transposit
mobil
element
rnase
bertrand
et
al
mcmanu
sharp
scherr
et
al
result
like
corrobor
current
accept
hypothesi
respons
dsrna
play
defens
physiolog
role
deleteri
rna
viru
transcript
therefor
mirna
essenti
mainten
genom
integr
larg
rang
biolog
therapeut
applic
hinder
due
poor
cellular
uptak
absenc
mechan
deliv
sirna
specifi
calli
target
cell
c
aptamerdirect
sirna
deliveri
target
cell
sirna
coupl
aptam
specif
bind
surfac
epitop
target
cell
ie
prostatespecifi
c
membran
antigen
therebi
possibilit
specif
downregul
gene
express
cancer
cell
follow
bind
sirnaaptam
chimera
cellsurfac
receptor
receptoroligonucleotid
complex
intern
follow
induct
rna
interfer
system
zamor
interfer
effect
dsrna
nonstoichiometr
relat
homolog
mrna
sinc
low
amount
dsrna
caus
strong
interfer
suggest
rnai
effect
involv
catalyt
stage
base
titrat
endogen
mrna
sverdlov
current
sirna
drug
develop
order
inhibit
cell
infect
hiv
martinez
et
al
infl
uenza
virus
ge
et
al
treat
autoimmun
hepat
song
et
al
fig
rnai
also
use
tool
studi
signal
pathway
involv
neurogenesi
neurodegener
miller
et
al
exampl
function
vascular
endotheli
growth
factor
vegf
direct
neurogenesi
verifi
ed
via
rnai
cao
et
al
anoth
approach
use
adenovir
lentivir
aav
adenoassoci
viral
deliveri
system
chen
et
al
treat
spinocebellar
ataxia
xia
et
al
amyotroph
later
sclerosi
al
ralph
et
al
raoul
et
al
harper
et
al
rodriguezlebron
et
al
alzheim
diseas
singer
et
al
compar
gene
ablat
tool
antinsens
oligonucleotid
sirna
notabl
superior
due
higher
degre
mrna
degrad
low
potenti
induct
immun
respons
bertrand
et
al
sinc
sirna
molecul
integr
genom
plasmid
potenti
caus
collater
effect
thu
much
therapeut
advantag
smallinterf
rna
need
transfer
nucleu
order
present
activ
requir
less
sophist
deliveri
system
addit
due
rel
small
size
deliveri
cocktail
sirna
target
express
multipl
diseas
caus
gene
time
feasibl
vegf
gene
express
fi
rst
target
clinic
trial
use
sirna
treatment
agerel
macular
degener
amd
rnai
also
use
combat
infect
respiratori
syncyti
viru
rsv
genom
vehicl
use
case
salin
formul
success
trial
may
due
direct
administr
sirna
diseas
organ
advantag
direct
administr
high
concentr
sirna
avail
target
side
sirnabas
drug
denomin
also
suppress
vegf
gene
express
current
test
phase
trial
patient
suffer
amd
moreov
earli
also
test
phase
clinic
trial
treatment
diabet
macular
edema
http
wwwacuitypharmacom
sirna
develop
alnylam
pharmaceut
inc
treatment
rsv
infect
complet
two
phase
trial
appear
appropri
test
human
sirna
target
influenza
hepat
c
virus
protiva
biotherapeut
expect
avail
clinic
use
within
come
year
protiva
biotherapeut
stabil
sirna
plasma
sirna
molecul
unstabl
serum
result
degrad
serum
nucleas
thu
short
halfliv
vivo
soutschek
et
al
stabil
nucleas
degrad
achiev
introduc
phosphorothio
p
backbon
linkag
end
exonucleas
resist
modifi
cation
relat
endonucleas
resist
vornloch
et
al
li
et
al
choung
et
al
moreov
sirna
molecul
consist
entir
uoromodifi
ed
nucleotid
demonstr
enhanc
plasma
stabil
increas
vitro
potenc
duplex
contain
modifi
cation
present
increas
thermal
stabil
fold
resist
degrad
plasma
natur
rna
duplex
hoshika
et
al
substanti
improv
sirna
activ
plasma
stabil
also
achiev
judici
combin
modifi
cation
dand
et
al
aptam
oligonucleotid
identifi
ed
vitro
select
process
highaffi
niti
binder
given
target
molecul
purpos
dna
librari
synthes
contain
inner
random
sequenc
typic
nucleotid
fl
ank
two
outer
constant
region
nucleotid
promot
site
incorpor
one
constant
sequenc
rna
aptam
select
chemic
synthes
dna
pool
amplifi
pcr
presenc
senseand
antisenseprim
dna
templat
either
transcrib
vitro
rna
pool
denatur
origin
singlestrand
ss
dna
pool
use
vitro
select
process
mani
case
ed
pyrimidin
employ
vitro
transcript
reaction
improv
nucleaseresist
gener
rna
molecul
review
ulrich
et
al
reiter
cycl
vitro
select
also
denomin
systemat
evolut
ligand
exponenti
enrich
selex
carri
incub
target
protein
anoth
molecul
biolog
import
combinatori
dna
rna
pool
follow
elut
amplifi
cation
target
binder
rtpcr
pcr
techniqu
select
stringenc
increas
number
selex
cycl
increas
stringenc
achiev
augment
number
dna
rna
molecul
rel
possibl
target
bind
site
well
extens
wash
remov
lowaffi
niti
binder
procedur
ensur
origin
random
pool
contain
differ
sequenc
becom
narrow
homogen
popul
highaffi
niti
target
binder
bind
affi
niti
select
rna
dna
librari
target
longer
improv
subsequ
selex
cycl
fi
nal
pool
sequenc
identifi
cation
aptam
stage
one
expect
similar
sequenc
motif
preserv
aptam
bind
affi
niti
target
case
consensu
sequenc
fall
conserv
stemloop
motif
rna
dna
molecul
uniqu
bind
characterist
also
denomin
aptam
latin
aptu
fi
use
basic
research
clinic
diagnost
purpos
basic
research
purpos
includ
character
aptamertarget
protein
interact
cellular
context
ulrich
et
al
ulrich
et
al
studi
mechan
protein
activ
inactiv
hess
et
al
map
bind
site
shi
et
al
dissect
intracellular
signal
pathway
famulok
et
al
well
inhibit
intracellular
viru
replic
et
al
exampl
intracellular
act
aptam
intram
rna
molecul
select
highaffi
niti
ligand
protein
protein
express
drosophila
develop
act
genespl
process
exact
function
protein
fulli
understood
intram
develop
express
pentamer
structur
develop
drosophila
cell
observ
drastic
reduct
drosophila
surviv
presenc
aptam
indic
crucial
function
protein
shi
et
al
anoth
approach
therapeut
make
use
aptam
bind
intracellular
domain
integrin
lymphocyt
functionassoci
portion
mediat
cell
adhes
bind
intercellular
adhes
specifi
c
blockag
signal
pathway
vivo
intram
could
potenti
appli
signaltransduct
cascad
blind
et
al
intram
rev
protein
involv
cycl
replic
hiv
result
inhibit
viru
replic
cell
cultur
good
et
al
human
lymphocyt
cell
chaloin
et
al
result
indic
intram
may
altern
rnai
specifi
calli
suppress
activ
gene
product
instead
induc
degrad
mrna
code
protein
abil
modul
intram
activ
would
drastic
increas
effi
cienci
regul
intracellular
signal
oligonucleotid
activ
aptam
could
put
alloster
control
second
molecul
tang
breaker
express
could
alloster
regul
sequenc
code
intram
introduc
posit
work
induct
promot
intram
develop
kanamicin
tobramicin
express
posit
promot
addit
antibiot
cell
system
result
shut
transcript
werstuck
green
high
specifi
citi
aptam
act
isotyp
splicevari
target
protein
make
excel
drug
candid
regard
thei
colleagu
identifi
ed
intram
bind
switch
guanin
nucleotid
exchang
affect
homolog
protein
differ
function
effect
observ
follow
six
hour
hela
cell
transfect
aptam
construct
thei
et
al
properti
intram
make
promis
tool
develop
therapeut
applic
vaccin
develop
blockag
intracellular
transduct
pathway
viral
infect
control
timedepend
gene
knockdown
protein
activ
suppress
target
protein
activ
desir
time
point
follow
aptam
inactiv
may
gain
import
control
import
physiolog
function
blood
coagul
rusconi
et
al
inhibit
coagul
instanc
desir
patholog
condit
high
blood
pressur
must
immedi
revers
case
hemorrhag
moreov
aptam
potent
inhibitor
extracellular
protein
activ
instanc
block
growth
factorreceptor
bind
antivegf
aptam
develop
block
patholog
vegf
receptor
bind
therebi
leav
vital
vegf
isoform
action
unaffect
antivegf
aptam
formul
recent
approv
therapeut
use
fda
tradenam
macugen
review
ulrich
et
al
vavva
damico
ng
et
al
anoth
promis
aptam
test
clinic
trial
denomin
regado
bioscienc
therapeut
aptam
target
factor
ixa
drug
anticoagul
activ
aptam
complementari
oligonucleotid
antidot
test
healthi
volunt
phase
pharmacodynam
evalu
dyke
et
al
signifi
cant
bleed
occurr
associ
treatment
aptam
drug
antidot
well
toler
overal
result
pharmacokinet
two
compound
healthi
volunt
indic
safe
use
human
encourag
studi
dyke
et
al
addit
possibl
therapeut
relev
aptam
may
use
diagnost
applic
differenti
normal
tumor
vasculatur
blank
et
al
pathogen
form
prion
protein
normal
conform
rhie
et
al
well
identifi
possibl
biohazard
anthrax
spore
bruno
kiel
possibl
pharmaceut
therapeut
import
aptam
mainli
relat
follow
characterist
affi
niti
target
dissoci
constant
nanoto
picomolar
rang
similar
found
monoclon
antibodyantigen
complex
highaffi
niti
aptamerprotein
interact
result
specifi
c
hydrogenbond
format
base
amino
acid
target
protein
addit
interact
oligonucleotid
backbon
protein
secondari
tertiari
structur
ii
aptam
chemic
modifi
acquir
stabil
vivo
applicaton
result
increas
halflif
time
coupl
second
day
ulrich
et
al
modifi
cation
oligonucleotid
structur
done
prior
follow
selex
process
iii
identifi
ed
aptam
sequenc
truncat
minim
sequenc
repres
singl
loop
structur
suffi
cient
bind
biolog
activ
iv
aptam
easili
enzymat
reproduc
produc
larg
scale
chemic
synthesi
review
ulrich
et
al
combin
targetspecifi
c
drug
deliveri
control
releas
langer
import
goal
search
effi
cient
less
hazard
treatment
tumor
diseas
desir
cytotox
drug
dosag
deliv
target
cell
long
time
span
therebi
spare
healthi
cell
surround
tissu
order
attain
object
critic
develop
special
vessel
encapsul
chemotherapeut
drug
control
releas
vessel
direct
cancer
cell
ie
present
appropri
ligand
recogn
specifi
c
cancercel
antigen
wide
varieti
addressmolecul
investig
effi
cienci
deliv
oligonucleotid
cancer
cell
human
antibodi
singl
chain
variabl
fragment
gener
murin
hybridoma
phage
display
minibodi
peptid
among
test
deliveri
vehicl
review
weiner
adam
develop
vehicl
prerequisit
must
satisfi
ed
order
improv
chanc
pass
function
clinic
trial
drug
encapsul
particlesystem
must
compos
biocompat
biodegrad
polym
approv
clinic
use
drug
regul
agenc
moreov
vessel
particl
must
effi
cientli
bind
neg
charg
na
chain
minim
adverseeffect
tridimension
fold
thu
bind
properti
deliveri
vessel
must
yet
effi
cientli
select
bind
target
cell
well
long
halflif
circul
order
reach
target
degrad
releas
content
vehicl
may
classifi
ed
improv
oligonucleotid
pharmacokinet
attach
highmolecular
weight
lipophil
molecul
aptam
order
augment
halflif
therapeut
oligonucleotid
plasma
ii
permit
immobil
oligonucleotid
pass
physiolog
barrier
brainblood
barrier
plasma
membran
deliv
cell
addit
abil
act
therapeut
drug
aptam
also
use
vehicl
deliv
anoth
oligonucleotid
specifi
c
target
cell
farokhzad
et
al
prostatespecifi
c
membran
antigen
psma
integr
membran
glycoprotein
express
prostat
carcinoma
surfac
new
vessel
form
variou
solid
tumor
antigen
highli
express
everi
stage
prostat
cancer
develop
rajasekaran
et
al
therefor
strong
molecular
target
candid
immunotherapi
prostatecanc
imag
previou
effort
select
destroy
cancer
cell
gener
made
use
antibodi
deliv
cytotox
packag
wu
senter
howev
aptam
develop
psma
protein
anoth
molecul
biolog
import
potent
target
binder
use
instead
antibodi
deliv
cytotox
agent
cancer
cell
farokhzad
et
al
gelonin
gel
protein
toxin
nglycosidas
activ
promot
cell
death
cleavag
specif
glycosid
bond
rrna
therebi
promot
inhibit
protein
synthesi
result
elimin
target
cell
howev
gelonin
contain
transloc
domain
mani
ribosom
toxin
incorpor
cell
consider
quantiti
rosenblum
et
al
order
improv
cytotox
recombin
gel
rgel
develop
although
recombin
variant
provok
toxic
target
cell
membraneperm
significantli
improv
rosenblum
et
al
problem
solv
chemic
conjug
rgel
genet
fusion
deliveri
packag
recognit
molecul
addit
cystein
residu
form
antibodi
immunoconjug
rosenblum
et
al
better
et
al
instanc
cytokin
vegf
coupl
gelonin
result
conjug
specifi
calli
kill
cancer
cell
overexpress
vegf
receptor
veenenda
et
al
select
drug
home
specifi
c
target
cell
tissu
therapeut
nanoparticl
desir
aim
deliveri
system
previous
select
rna
aptam
specifi
calli
bind
psma
use
escort
gel
tumor
cell
express
psma
surfac
conjug
toxin
destroy
prostat
cancer
cell
ic
valu
nm
present
increas
toxic
time
comparison
cell
express
psma
chu
et
al
extracellular
domain
psma
recogn
biocompat
biodegrad
polymer
nanoparticl
encapsul
docetaxel
dtxl
surfac
function
stabl
nucleaseresist
rna
aptam
contain
pyrimidin
base
farokhzad
et
al
aptamernanoparticl
bioconjug
dtxlnpapt
bound
psma
protein
express
surfac
prostat
epitheli
cell
lncap
easili
incorpor
cancer
cell
cytotox
effect
vitro
encouragingli
dtxlnpapt
bioconjug
also
present
remark
effi
caci
reduc
side
effect
vivo
observ
strongli
indic
potenti
therapeut
applic
aptamernanoparticl
bioconjug
specif
target
destroy
cancer
cell
anoth
approach
possibl
therapeut
applic
make
use
packag
rna
prna
part
dnapackag
machineri
bacteriophag
prna
genet
engin
origin
chimer
rna
form
dimer
via
interlock
rightand
lefthand
loop
fuse
prna
either
receptorbind
rna
aptam
folat
small
interf
rna
sirna
ribozym
anoth
chemic
group
disturb
dimer
format
interfer
function
insert
moieti
incub
cancer
cell
prna
dimer
one
subunit
harbor
receptorbind
moieti
containin
gene
expressionsilenc
molecul
result
targetcel
recognit
uptak
cell
subsequ
silenc
antiapoptot
gene
express
chimer
prna
complex
found
process
function
doublestrand
sirna
rnaspecifi
c
endonucleas
dicer
anim
trial
confi
rmed
suppress
tumorigen
cancer
cell
ex
vivo
deliveri
khale
et
al
smallsiz
rna
nanoparticl
allow
repeat
longterm
administr
avoid
problem
short
retent
time
small
molecul
also
avoid
deliveri
problem
particl
larger
nm
farokhzad
collabor
synthes
polylact
acid
pla
blockpolyethylen
glycol
peg
copolym
carboxil
termin
function
group
plapegcooh
encapsul
rhodaminelabel
dextran
insid
plapegcooh
nanoparticl
nanoparticl
neg
charg
carboxil
group
surfac
minim
unspecifi
c
interact
neg
charg
na
instanc
conjug
aminomodifi
ed
na
clinic
trial
reveal
presenc
antipsma
aptam
target
cell
increas
bioconjug
nanoparticl
farokhzad
et
al
incub
proteinfre
nanoscal
particl
contain
receptorbind
aptam
ligand
may
result
bind
intern
trival
therapeut
particl
dtxlnpapt
plapegcoohapt
subsequ
modul
prostat
cancer
cell
apoptosi
bioconjug
base
materi
priorli
approv
clinic
use
fda
sinc
molecul
small
rel
stabl
nonimmunogen
easi
synthes
translat
bioconjug
clinic
practic
facilit
therefor
therapeut
diagnost
nanoparticleaptam
bioconjug
shortli
develop
import
human
diseas
regard
rna
molecul
might
use
build
block
mani
associ
nanotechnolog
deliveri
macromolecul
includ
globular
protein
aptam
sclera
therapeut
eye
diseas
describ
recent
studi
ambati
et
al
ambati
et
al
transport
potenti
diffus
molecul
sclera
take
place
extens
surfac
area
contain
high
percentag
water
water
main
constitu
extracellular
matrix
contain
cell
unchang
permeabl
age
olsen
et
al
olsen
et
al
boubriak
et
al
use
rout
administr
could
avoid
problem
limit
deliveri
approach
treatment
viral
system
diseas
kamei
et
al
dayl
lang
sinc
transscler
deliveri
system
may
destruct
ie
iontophoresi
occasion
provok
retin
necrosi
gliosi
lam
et
al
ideal
approach
would
develop
biodegrad
polimer
particl
prolong
deliveri
capac
lenghten
protein
na
releas
timespan
would
allow
effi
cient
address
drug
specifi
c
target
tissu
carrasquillo
et
al
carrasquillo
et
al
carrasquillo
et
al
frazza
schmitt
develop
poli
lacticcoglycol
acid
plga
polym
sinc
wide
use
clinic
procedur
sutur
tissu
engin
hasirci
et
al
choi
plga
may
local
appli
allow
intralesion
administr
drug
minim
advers
system
effect
possibl
local
applic
plga
constitut
import
pharmacolog
advantag
malleri
et
al
moritera
et
al
employ
plga
drug
deliveri
system
therapi
ocular
diseas
reveal
sign
ocular
toxic
infl
ammatori
process
even
long
treatment
period
moritera
et
al
giordano
et
al
howev
advers
side
effect
result
sclerotomi
result
deliveri
procedur
small
encapsul
synthet
drug
carrasquillo
et
al
develop
drug
deliveri
system
continu
releas
antivegf
aptam
macugen
control
fashion
signifi
cant
time
span
local
administ
extern
area
sclera
use
propos
deliveri
system
releas
macugen
illustr
promiss
altern
tansscler
deliveri
drug
treatment
ocular
choroid
ill
anoth
way
success
home
aptam
subcellular
target
express
cell
interest
case
express
drug
would
use
treatment
hereditari
diseas
well
viral
diseas
aid
tar
region
rna
genom
attract
target
inhibitori
nabas
drug
tar
nucleotid
regulatori
element
present
end
everi
viral
rna
particl
exert
crucial
role
viral
transcript
recogn
ternari
complex
compos
tat
viral
protein
transactiv
transcript
two
cellular
protein
name
cyclin
herrmann
mancini
richter
et
al
associ
tat
hyperphosphoril
carboxytermin
rna
polymeras
ii
subsequ
activ
transcript
machineri
trigger
effi
cient
synthesi
entir
viral
rna
nabas
drug
strongli
interact
tar
compet
format
transcript
complex
consequ
inhibit
transactiv
transcript
apparatu
thu
replic
compromis
moreov
sinc
tar
element
locat
close
proxim
end
matur
mrna
tar
binder
could
interfer
ribosom
machineri
well
na
includ
antisens
oligonuvleotid
sirna
aptam
employ
mani
studi
target
tar
element
turner
et
al
yoshinari
et
al
antitar
rna
aptam
optim
chemic
modifi
cation
toward
improv
stabil
regard
nucleas
resist
decreas
transactiv
transcript
cell
nuclei
extract
assay
darfeuil
et
al
darfeuil
et
al
darfeuil
et
al
kolb
et
al
et
al
aptam
also
develop
interf
gene
express
antihiv
revbind
aptam
rbeapt
konopka
et
al
konopka
collabor
use
cation
liposom
deliveri
vessel
carri
associ
rbeapt
ribozym
act
env
gene
inhibit
viral
product
konopka
et
al
data
provid
strong
evid
therapeut
potenti
na
ligand
antihiv
agent
intracellular
deliveri
effi
cient
conjug
na
termin
lipophil
molecul
report
improv
direct
cellular
uptak
exampl
sirna
conjug
cholesterol
improv
vitro
vivo
permeat
liver
cell
lorenz
et
al
number
approachesinclud
lipidbas
formul
transmesseng
niu
et
al
complex
polyethylenimin
grzelinski
et
al
cholesterololigoarginin
protaminefab
fusion
protein
song
et
al
atelocollagen
takei
et
al
minakuchi
et
al
shown
facilit
deliveri
tumor
cell
aptamersirna
chimer
rna
also
success
use
facilit
sirna
deliveri
vivo
mcnamara
et
al
chu
et
al
c
soutschek
cowork
demonstr
effect
silenc
gene
express
apolipoprotein
apob
intraven
administr
chemic
modifi
ed
sirna
result
silenc
apob
mrna
liver
jejunum
decreas
plasma
level
apob
protein
reduc
total
cholesterol
concentr
mice
soutschek
et
al
judg
et
al
made
use
sirna
duplex
formul
stabl
na
lipid
particl
snalp
attain
gene
silenc
apob
mice
zimmermann
et
al
moreov
gener
applic
snalp
formul
hepat
deliveri
sirna
demonstr
anim
model
hbv
ebola
viru
infect
morrissey
et
al
geisbert
et
al
oncolog
direct
deliveri
sirna
viral
deliveri
small
hairpin
sh
rna
tumor
shown
success
inhibit
xenograft
growth
mous
model
technolog
mediat
target
deliveri
sirna
need
improv
therapeut
effi
caci
safeti
use
human
lupold
et
al
identifi
ed
two
aptam
bind
low
nanomolar
affin
extracellular
portion
psma
two
aptam
denomin
share
consensu
sequenc
bound
differ
site
psma
distinct
mode
inhibit
suggest
aptam
identifi
es
uniqu
extracellular
epitop
recombin
psma
xpsm
aptam
fi
rst
recogn
specifi
c
prostat
cancer
marker
chu
et
al
coupl
sirna
interf
laminin
gapdh
gene
express
modular
streptavidin
bridg
aptam
bind
prostatecanc
cell
comparison
oligofectamin
invitrogen
aptamermedi
sirna
transfect
result
similar
inhibit
targetprotein
express
evalu
realtim
pcr
experi
psma
endocytosi
lncap
cell
thought
predominantli
proceed
via
clathrinco
pit
rate
intern
previous
measur
use
antibodi
direct
psma
also
presenc
antipsma
aptam
intern
shown
take
place
type
target
agent
within
hour
bind
farokhzad
et
al
inhibit
targetgen
express
detect
h
sirnaaptam
transfect
mcnamara
et
al
gener
chimera
sirna
construct
target
pololik
kinas
yano
et
al
reaganshaw
ahmad
two
surviv
gene
overexpress
human
tumor
takai
et
al
eckerdt
et
al
cori
adam
sinc
dicer
also
act
chimer
rna
aptamersirna
direct
rnai
pathway
silenc
cognat
mrna
aptamersirna
chimeramedi
gene
silenc
depend
dicer
activ
occur
via
rnai
pathway
howev
inhibit
dicer
activ
effect
transfect
sirnamedi
silenc
contain
sirna
shown
bypass
dicer
step
murchison
et
al
chimera
specifi
calli
bound
psma
surfac
lncap
cell
interact
prostat
cancer
cell
express
psma
see
scheme
combin
shrna
aptam
specifi
c
gene
express
control
target
cell
accomplish
et
al
research
group
construct
vector
contain
theophyllinebind
aptam
jenison
et
al
zimmermann
et
al
loop
region
shrna
target
enhanc
green
fl
uoresc
protein
egfp
promot
express
construct
cotransfect
construct
code
egfp
express
hek
cell
shrnainduc
egfp
gene
express
silenc
dosedepend
inhibit
increas
concentr
theophyllin
aptamerbound
theophyllin
interf
dicercleavag
site
studi
prove
feasibl
modul
gene
express
control
intracellular
protein
cell
metabolit
one
fastest
approv
ever
obtain
drug
fda
imatinib
imatinib
mesyl
gleevec
novarti
treatment
chronic
myelogen
leukemia
cml
although
incid
cml
low
rate
cure
convent
treatment
poor
gleevec
tyrosin
kinas
inhibitor
affect
leukem
cell
caus
fusion
two
gene
bcr
abl
chromosom
shuffl
chromosom
although
expens
gleevec
oral
drug
led
remiss
cmlrelaps
patient
howev
work
well
blast
crisi
current
activ
cytrx
corpor
concentr
develop
small
molecul
drug
rnai
drug
discoveri
dna
vaccin
deliveri
technolog
multipl
applic
area
dna
vaccin
gene
therapi
proprietari
poloxam
compound
tranzfect
reveal
good
result
regard
transfect
abil
immunoadjuv
activ
toxic
profi
le
prerequisit
dnabas
vaccin
compani
also
particip
develop
genesilenc
technolog
treatment
amyotroph
later
sclerosi
type
ii
diabet
cmv
retin
obes
cancer
target
epiderm
growth
factor
egf
receptor
pegyl
immunoliposom
carri
plasmid
code
shrna
prolong
surviv
mice
intracrani
human
brain
cancer
zhang
et
al
observ
encapsul
oligonucleotid
readili
pass
bloodbrain
barrier
encourag
develop
nabas
therapi
neurodegen
diseas
review
sa
nanotechnolog
fi
eld
aptam
potenti
act
target
molecul
direct
deliveri
nanoparticl
antigen
present
surfac
target
cell
gener
term
therapeut
nanoparticl
compon
special
deliveri
vehicl
encapsul
drug
drug
releas
occur
regul
defi
ned
manner
depend
therapeut
demand
devic
design
ensur
continu
immedi
drug
releas
combin
target
deliveri
control
releas
drug
affect
tissu
site
lead
develop
smart
therapeut
effect
less
undesir
side
effect
drug
avail
today
sever
studi
shown
nanoparticl
attach
na
way
nabind
properti
target
preserv
thu
reduc
potenti
associ
deleteri
side
effect
new
approach
supplement
convent
chemotherapi
radiotherapi
cancer
treatment
prevent
drug
resist
damag
normal
tissu
view
impact
genom
revolut
improv
medicin
healthcar
stateoftheart
na
carrier
togeth
highli
specifi
c
oligonucleotid
drug
may
help
reduc
side
effect
drug
therapi
